Brown Gibbons Lang & Company Presents: DxPx U.S. at ADLM 2024

DxPx U.S. is an industry + investor partnering conference dedicated to Diagnostics, Digital Health, Precision Medicine, and Life Sciences Tools

Chicago, IL — April 3, 2024 — Brown Gibbons Lang & Company (BGL), a leading independent investment banking and financial advisory firm, is pleased to present DxPx U.S., the industry + investor partnering conference dedicated to Diagnostics, Digital Health, Precision Medicine, and Life Sciences Tools. DxPx U.S. takes place this year from July 30th to August 1st in Chicago, Illinois within the exposition hall of ADLM 2024 (formerly the AACC Annual Scientific Meeting & Clinical Lab Expo), the premier global laboratory medicine meeting.

To register for DxPx U.S. 2024, visit:

Established in 2019 in Dusseldorf, Germany by Dr. Mirko Stange, a scientist and entrepreneur, DxPx was created to address the underrepresentation of diagnostics in partnering conferences compared to other life sciences fields. DxPx addresses this need in the market and facilitates connections between companies and investors in Diagnostics, Digital Health, Precision Medicine, and Life Sciences Tools.

BGL joined DxPx as an organizing sponsor in its first year due to the firm’s deep experience across the diagnostics, research tools, lab equipment, and medical devices landscape, bringing valuable expertise in life sciences capital formation, technology strategy, corporate ventures, and mergers & acquisitions to DxPx participants. DxPx EU is now established as an annual destination conference for the Diagnostics & Research Tools industry in Europe. In 2022, BGL and Stange brought DxPx to the United States in partnership with AACC, now known as the Association for Diagnostics & Laboratory Medicine (ADLM), making 2024 the third year of partnership between these organizations.

With more than 900 exhibitors across more than 200 product categories, proximity to ADLM 2024 offers a unique networking opportunity for DxPx U.S. attendees and unparalleled brand exposure for DxPx sponsors, exhibitors, and presenters. DxPx U.S. offers a one-of-a-kind conference experience for all participants across the industry:

  • Pre-Scheduled 1×1 Meetings offer the ability to maximize your time at DxPx & ADLM 2024, including the use of our private meeting rooms
  • Exclusive Networking Events connect startups, growth-stage companies, investors & accelerators and their portfolio companies, tech scouts, service providers, and others
  • Panel Presentations feature industry knowledge & market insights from leading healthcare industry experts and private equity investors
  • Startup City spotlights the most innovative HealthTech and MedTech startups within the ADLM 2024 Clinical Lab Expo
  • The 42PLUS1 Pitch Competition gives eight startups the chance to present their business plans and compete for up to $2 million in funding

BGL’s Healthcare & Life Sciences team has decades of experience advising companies across the diagnostics, research tools, lab equipment, and device landscape. We have provided capital formation, technology strategy, corporate ventures, and medical device M&A strategy for a wide range of companies. Additionally, we maintain active relationships with global industry participants and capital providers, and closely follow regulatory and reimbursement trends. Our sector involvement enables us to not only provide unique access to capital providers, but also identify and execute strategic opportunities for our investment banking clients.

About Brown Gibbons Lang & Company

Brown Gibbons Lang & Company (BGL) is a leading independent investment bank and financial advisory firm focused on the global middle market. The firm advises private and public corporations and private equity groups on mergers and acquisitions, capital marketsfinancial restructuringsbusiness valuations and opinions, and other strategic matters. BGL has investment banking offices in Chicago, Cleveland, Los Angeles, and New York, and real estate offices in Chicago, Cleveland, and San Antonio. The firm is also a founding member of Global M&A Partners, enabling BGL to service clients in more than 35 countries around the world. Securities transactions are conducted through Brown, Gibbons, Lang & Company Securities, LLC, an affiliate of Brown Gibbons Lang & Company LLC and a registered broker-dealer and member of FINRA and SIPC. For more information, please visit

Oliver Dick

Oliver brings 30+ years of experience in the life sciences industry, has worked in pharma, biotechnology and in vitro diagnostics. His areas of expertise fall under Supply Chain Management, Planning, Production, QC, QA, Engineering, Technology Transfer and Process Improvement. Amongst his vast experience, Oliver held functions such as Vice President of Global Manufacturing at QIAGEN, Chief Operating Officer at Miltenyi Biotec or Chief Operating Office of Resolve Biosciences. He demonstrated exceptional leadership and expertise in driving manufacturing excellence on a global scale.

Oliver has a proven ability to streamline processes, optimize production efficiency, and foster a culture of innovation. He was responsible for strategy development, scaling, cost control and quality and was part of multiple M&A projects and transfer of many new products from acquisition or own development. Today Oliver offers his expertise mainly through his own Consultancy Service Company ODICON.


Christoph Brandenberger is a Managing Director at BGL and a leader in the firm’s Diagnostics, Research Tools & Medical Devices investment banking group. He has more than 20 years of experience in all aspects of mergers and acquisitions, commercialization and partnering agreements, and private placements.

A native of Austria and fluent in German, Christoph’s investment banking experience, coupled with his background in international business, has made him a sought-after advisor in both the domestic and international healthcare markets.

Prior to joining BGL, Christoph served as managing director for Healthios Capital Markets, LLC. Christoph started his career as a financial analyst for Bank of America Securities.


John Riddle

John Riddle is a Managing Director and member of the BGL Executive Committee. He has more than 30 years of investment banking and capital markets experience, advising clients across a broad spectrum of mergers and acquisitions, capital markets activities, and strategic assignments.

John leads BGL’s advisory activities in the Healthcare & Life Sciences investment banking group, which comprises both corporate investment banking and real estate capital markets capabilities. Together with his team, John maintains an ongoing coverage effort with broad activity across several sectors, including health facilities, physician services, and ancillary providers; diagnostics and research tools; medical device and products; and select healthcare technology verticals, including payor services, data analytics, and clinical automation.


Dr. Mirko Stange

Born in Bremen, Germany in 1974, Dr. Mirko Stange is a diagnostics and life sciences expert with a proven track record in turning around and commercializing innovations. He possesses extensive executive management experience, having led diagnostics and biotech startups, as well as developing and conducting consulting products. Following the completion of his Ph.D. in Biochemistry and Biophysics at the University of North Carolina at Chapel Hill, Dr. Stange began his career in 2004 at the strategy consultancy McKinsey. Subsequently, he worked with the turnaround-specialized advisory firm Droege & Comp., primarily serving clients from the pharma and chemistry industry in Germany and Switzerland.

In 2008, he founded an independent Life Sciences consultancy in Germany where, to date, he leads and directs a team of international experts. This team identifies and funds SMEs with high potential for national and international leverage. In addition to his over ten years of experience in independent corporate finance and management consulting, Mirko Stange provides interim management services to selected clients. To date, three companies co-founded and managed/advised by Dr. Stange have been successfully exited. Leveraging his scientific background, he is also a named inventor on several granted and pending patents.


FName LName

Lorem ipsum dolor sit amet, consectetur adipiscing elit. Ut elit tellus, luctus nec ullamcorper mattis, pulvinar dapibus leo.